A novel osteogenic oxysterol compound for therapeutic development to promote bone growth: Activation of hedgehog signaling and osteogenesis through smoothened binding

Journal of Bone and Mineral Research

Volumn 29, Issue 8, 2014, Pages 1872-1885

  Montgomery, Scott R ^a   Nargizyan, Taya ^b   Meliton, Vicente ^b   Nachtergaele, Sigrid ^c   Rohatgi, Rajat ^c   Stappenbeck, Frank ^b   Jung, Michael E ^a   Johnson, Jared S ^a   Aghdasi, Bayan ^a   Tian, Haijun ^a   Weintraub, Gil ^a   Inoue, Hirokazu ^a   Atti, Elisa ^a   Tetradis, Sotirios ^a   Pereira, Renata C ^a   Hokugo, Akishige ^a   Alobaidaan, Raed ^a   Tan, Yanlin ^a   Hahn, Theodor J ^d   Wang, Jeffrey C ^e   Parhami, Farhad ^b   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Adipogenesis; BMP 2; Osteogenesis; Oxysterol; Spinal Fusion

Indexed keywords

ALKALINE PHOSPHATASE; ANABOLIC AGENT; BONE SIALOPROTEIN; CYCLOPAMINE; LUCIFERASE; OSTEOCALCIN; OXY 133; OXYSTEROL; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; BONE DENSITY CONSERVATION AGENT; OXY133; SONIC HEDGEHOG PROTEIN; STEROL;

ADIPOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DEVELOPMENT; BONE GROWTH; BONE MASS; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; ENCHONDRAL OSSIFICATION; FIBROBLAST; HEDGEHOG; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENCHYMAL STEM CELL; MICRO-COMPUTED TOMOGRAPHY; MOUSE EMBRYO; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; OSSIFICATION; RAT; SPINE FUSION; STROMA CELL; STRUCTURE ACTIVITY RELATION; TISSUE VOLUME; ANIMAL; CELL DIFFERENTIATION; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LEWIS RAT; MOUSE; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL LINE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HEDGEHOG PROTEINS; MALE; MICE; MOLECULAR STRUCTURE; OSTEOGENESIS; RATS; RATS, INBRED LEW; SIGNAL TRANSDUCTION; STEROLS;

EID: 84904674458     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2213     Document Type: Article

References (37)

1. Johnson EE, Urist MR., Human bone morphogenetic protein allografting for reconstruction of femoral nonunion. Clin Orthop Relat Res. 2000; 371: 61-74.
2. Mundy GR., Directions of drug discovery in osteoporosis. Annu Rev Med. 2002; 53: 337-54.
3. Rodan GA, Martin TJ., Therapeutic approaches to bone diseases. Science. 2000; 289: 1508-14.
4. Yoon ST, Boden SD., Osteoinductive molecules in orthopaedics: basic science and preclinical studies. Clin Orthop Relat Res. 2002; 395: 33-43.
5. Arrington ED, Smith WJ, Chambers HG, Bucknell AL, Davino NA., Complications of iliac crest bone graft harvesting. Clin Orthop Relat Res. 1996; 329: 300-9.
6. Vaccaro AR, Chiba K, Heller JG, et al. Bone grafting alternatives in spinal surgery. Spine J. 2002; 2: 206-15.
7. Rihn JA, Kirkpatrick K, Albert TJ., Graft options in posterolateral and posterior interbody lumbar fusion. Spine. 2010; 35: 1629-39.
8. Mitka M., Questions about spine fusion product prompt a new process for reviewing data. JAMA. 2011; 306: 1311-2.
9. Lewandrowski K-U, Nanson C, Calderon R., Vertebral osteolysis after posterior interbody lumbar fusion with recombinant human bone morphogenetic protein 2: a report of five cases. Spine J. 2007; 7: 609-14.
10. Wong DA, Kumar A, Jatana S, Ghiselli G, Wong K., Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). Spine J. 2008; 8: 1011-8.
11. Smucker JD, Rhee JM, Singh K, Yoon ST, Heller JG., Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine. Spine. 2006; 31: 2813-9.
12. Carragee EJ, Hurwitz EL, Weiner BK., A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 2011; 11: 471-91.
13. Kha HT, Basseri B, Shouhed D, et al. Oxysterols regulate differentiation of mesenchymal stem cells: pro-bone and anti-fat. J Bone Miner Res. 2004; 19: 830-40.
14. Kim W-K, Meliton V, Amantea CM, Hahn TJ, Parhami F., 20(S)- hydroxycholesterol inhibits PPARgamma expression and adipogenic differentiation of bone marrow stromal cells through a Hedgehog-dependent mechanism. J Bone Miner Res. 2007; 22: 1711-9.
15. Johnson JS, Meliton V, Kim WK, et al. Novel oxysterols have pro-osteogenic and anti-adipogenic effects in vitro and induce spinal fusion in vivo. J Cell Biochem. 2011; 112: 1673-84.
16. Zhao L, Li G, Chan K, Wang Y, Tan P., Comparison of multipotent differentiation potentials of murine primary bone marrow stromal cells and mesenchymal stem cell line C3H10T1/2. Calcif Tissue Int. 2009; 84: 56-64.
17. Parhami F, Morrow AD, Balucan J, et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol. 1997; 17: 680-7.
18. Dwyer JR, Sever N, Carlson M, Nelson SF, Beachy PA, Parhami F., Oxysterols are novel activators of the Hedgehog signaling pathway in pluripotent mesenchymal cells. J Biol Chem. 2007; 282: 8959-68.
19. Kim W-K, Meliton V, Bourquard N, Hahn TJ, Parhami F., Hedgehog signaling and osteogenic differentiation in multipotent bone marrow stromal cells are inhibited by oxidative stress. J Cell Biochem. 2010; 111: 1199-209.
20. Nachtergaele S, Mydock LK, Krishnan K, et al. Oxysterols are allosteric activators of the oncoprotein Smoothened. Nat Chem Biol. 2012; 8: 211-20.
21. Rohatgi R, Milenkovic L, Corcoran RB, Scott MP., Hedgehog signal transduction by Smoothened: pharmacologic evidence for a 2-step activation process. Proc Natl Acad Sci U S A. 2009; 106: 3196-201.
22. Alanay A, Chen C, Lee S, et al. The adjunctive effect of a binding peptide on bone morphogenetic protein enhanced bone healing in a rodent model of spinal fusion. Spine. 2008; 33: 1709-13.
23. Miyazaki M, Sugiyama O, Tow B, et al. The effects of lentiviral gene therapy with bone morphogenetic protein-2-producing bone marrow cells on spinal fusion in rats. J Spinal Disord Tech. 2008; 21: 372-9.
24. Pereira RC, Stadmeyer LE, Smith DL, Rydziel S, Canalis E., CCAAT/Enhancer-binding protein homologous protein (CHOP) decreases bone formation and causes osteopenia. Bone. 2007; 40: 619-26.
25. Magyar CE, Aghaloo TL, Atti E, Tetradis S., Ostene, a new alkylene oxide copolymer bone hemostatic material, does not inhibit bone healing. Neurosurgery. 2008; 63: 373-8; discussion 378.
26. Nedelcu D, Liu J, Xu Y, Jao C, Salic A., Oxysterol binding to the extracellular domain of Smoothened in Hedgehog signaling. Nat Chem Biol. 2013 Sep; 9 (9): 557-64.
27. Richardson JA, Amantea CM, Kianmahd B, et al. Oxysterol-induced osteoblastic differentiation of pluripotent mesenchymal cells is mediated through a PKC- and PKA-dependent pathway. J Cell Biochem. 2007; 100: 1131-45.
28. Amantea CM, Kim WK, Meliton V, Tetradis S, Parhami F., Oxysterol-induced osteogenic differentiation of marrow stromal cells is regulated by Dkk-1 inhibitable and PI3-kinase mediated signaling. J Cell Biochem. 2008; 105: 424-36.
29. Sintuu C, Simon RJ, Miyazaki M, et al. Full-length spp24, but not its 18.5-kDa proteolytic fragment, inhibits bone-healing in a rodent model of spine fusion. J Bone Joint Surg Am. 2011; 93: 1022-32.
30. Miyazaki M, Morishita Y, He W, et al. A porcine collagen-derived matrix as a carrier for recombinant human bone morphogenetic protein-2 enhances spinal fusion in rats. Spine J. 2009; 9: 22-30.
31. Zhu W, Rawlins BA, Boachie-Adjei O, et al. Combined bone morphogenetic protein-2 and -7 gene transfer enhances osteoblastic differentiation and spine fusion in a rodent model. J Bone Miner Res. 2004; 19: 2021-32.
32. Shields LBE, Raque GH, Glassman SD, et al. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine. 2006; 31: 542-7.
33. Baskin DS, Ryan P, Sonntag V, Westmark R, Widmayer MA., A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic protein-2 with the CORNERSTONE-SR allograft ring and the ATLANTIS anterior cervical plate. Spine. 2003; 28: 1219-24.
34. Robin BN, Chaput CD, Zeitouni S, Rahm MD, Zerris VA, Sampson HW., Cytokine-mediated inflammatory reaction following posterior cervical decompression and fusion associated with recombinant human bone morphogenetic protein-2: a case study. Spine. 2010; 35: E1350-4.
35. Garrett MP, Kakarla UK, Porter RW, Sonntag VKH., Formation of painful seroma and edema after the use of recombinant human bone morphogenetic protein-2 in posterolateral lumbar spine fusions. Neurosurgery. 2010; 66: 1044-9.
36. Stachniak JB, Diebner JD, Brunk ES, Speed SM., Analysis of prevertebral soft-tissue swelling and dysphagia in multilevel anterior cervical discectomy and fusion with recombinant human bone morphogenetic protein-2 in patients at risk for pseudarthrosis. J Neurosurg Spine. 2011; 14: 244-9.
37. Zara JN, Siu RK, Zhang X, et al. High doses of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation in vivo. Tissue Eng Part A. 2011; 17: 1389-99.